Virginia Medicaid Preferred Drug List
Annual Review Process – Round 2

The Virginia Medicaid Pharmacy and Therapeutics Committee (P&T) will be conducting round 2 of annual reviews for Phases II and III of the Preferred Drug List (PDL) program. The Virginia Medicaid program will continue utilizing Virginia specific contracts for pricing and supplemental rebates directly with manufacturers. Manufacturers are encouraged to provide supplemental rebate offers for consideration by the Commonwealth of Virginia.

The Department of Medical Assistance Services (DMAS) has set the anticipated schedule for review of the 6 drugs classes implemented in April 2004 (Phase II) and the eleven drug classes implemented in July 2004 (Phase III). Phase III contracts will be extended for 3 months; therefore, contracts for both phases will end on June 30, 2005. The following therapeutic classes of drugs will be reviewed for continued PDL inclusion in round 2:

Oral Hypoglycemics
Leukotriene Modifiers
Analgesic- NSAIDS (non-steroidal anti-inflammatory drugs)
Serotonin Receptor Agonists
Onychomycosis Antifungals
Bisphosphonates for Osteoporosis
Carbonic Anhydrase Inhibitors – Opthalmic
Alpha 2 Adrenergics – Opthalmic
Beta-blockers – Opthalmic
Prostaglandin Inhibitors – Opthalmic
Antihyperkinesis/CNS Stimulants (Medications For ADD/ADHD)
Macrolides - Adult (Antibiotics)
Macrolides - Pediatrics (Antibiotics)
Quinolones - Systemic (Antibiotics)
Long Acting Narcotics
2nd Generation Cephalosporins (Antibiotics)
3rd Generation Cephalosporins (Antibiotics)

• Thursday, December 23rd, 2004: A comprehensive bidding package with instructions will be sent electronically to manufacturers by First Health Services Corporation.

• Friday, February 4, 2005: Manufacturers' final supplemental rebate offers must be submitted to First Health Services by close of business. The Department expects to receive best and final offers by this date.

• March 2005: Meeting of the P&T Committee to review clinical information, pricing information, and to select which drugs will not require prior authorization.

• Friday, April 15, 2005: First Health Services must receive all manufacturer-executed supplemental rebate contracts by close of business. Should the final contract not be received at this time, previous offers will be considered rescinded.

• Monday, May 2, 2005: Final PDL posted on the DMAS website.

• Friday, July 1, 2005: Implement prior authorization requirement for drugs that were not selected to be on the PDL.

If you have any questions regarding the PDL process, please contact pdlinput@dmas.virginia.gov. All correspondence and inquiries regarding the annual review process should be directed to:

First Health Services Corporation
Attention: David Adams, Clinical Management Consultant

Rebate Contracting and Pricing
4300 Cox Road
Glen Allen, Virginia 23060
Phone: 804-965-7689
Email: adamsda@fhsc.